| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/JLCR.3414 |
| P698 | PubMed publication ID | 27264278 |
| P50 | author | Ashutosh Dash | Q43103898 |
| P2093 | author name string | Rubel Chakravarty | |
| Sudipta Chakraborty | |||
| K V Vimalnath | |||
| Priyalata Shetty | |||
| Ishita B Sen | |||
| P2860 | cites work | Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate | Q33346935 |
| Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer | Q33361082 | ||
| Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. | Q35604902 | ||
| Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer | Q35645376 | ||
| 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging | Q39389586 | ||
| Options to meet the future global demand of radionuclides for radionuclide therapy. | Q39527160 | ||
| 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer | Q39689821 | ||
| Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer | Q39808317 | ||
| Long-Term Retention of 177Lu/177mLu-DOTATATE in Patients Investigated by γ-Spectrometry and γ-Camera Imaging | Q40913291 | ||
| Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate | Q44958710 | ||
| Target burn-up corrected specific activity of 177Lu produced via 176Lu(n, gamma) 177Lu nuclear reactions. | Q47824947 | ||
| PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617. | Q50248450 | ||
| PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. | Q51766972 | ||
| [¹⁷⁷Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. | Q53031483 | ||
| PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. | Q53131398 | ||
| [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. | Q53176385 | ||
| Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis. | Q53790732 | ||
| P433 | issue | 9 | |
| P304 | page(s) | 364-371 | |
| P577 | publication date | 2016-06-06 | |
| P1433 | published in | Journal of Labelled Compounds and Radiopharmaceuticals | Q3186923 |
| P1476 | title | Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor. | |
| P478 | volume | 59 |
| Q91617685 | A review of prostate cancer imaging, positron emission tomography, and radiopharmaceutical-based therapy |
| Q62495036 | Current Strategies and Applications for Precision Drug Design |
| Q46401757 | Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer. |
Search more.